Tags

Type your tag names separated by a space and hit enter

Immunotherapy in Peripheral Neuropathies.
Neurotherapeutics. 2016 Jan; 13(1):96-107.N

Abstract

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

Authors+Show Affiliations

National Referral Center for Rare Neuromuscular Diseases, Institut Hospitalo-Universitaire de Neurosciences, University Hospital Pitié-Salpêtrière and University Pierre et Marie Curie (Paris VI), Paris, France. jean-marc.leger@aphp.fr.National Referral Center for Rare Neuromuscular Diseases, Institut Hospitalo-Universitaire de Neurosciences, University Hospital Pitié-Salpêtrière and University Pierre et Marie Curie (Paris VI), Paris, France.National Referral Center for Rare Neuromuscular Diseases, Institut Hospitalo-Universitaire de Neurosciences, University Hospital Pitié-Salpêtrière and University Pierre et Marie Curie (Paris VI), Paris, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26602549

Citation

Léger, Jean-Marc, et al. "Immunotherapy in Peripheral Neuropathies." Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, vol. 13, no. 1, 2016, pp. 96-107.
Léger JM, Guimarães-Costa R, Muntean C. Immunotherapy in Peripheral Neuropathies. Neurotherapeutics. 2016;13(1):96-107.
Léger, J. M., Guimarães-Costa, R., & Muntean, C. (2016). Immunotherapy in Peripheral Neuropathies. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, 13(1), 96-107. https://doi.org/10.1007/s13311-015-0401-7
Léger JM, Guimarães-Costa R, Muntean C. Immunotherapy in Peripheral Neuropathies. Neurotherapeutics. 2016;13(1):96-107. PubMed PMID: 26602549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunotherapy in Peripheral Neuropathies. AU - Léger,Jean-Marc, AU - Guimarães-Costa,Raquel, AU - Muntean,Cristina, PY - 2015/11/26/entrez PY - 2015/11/26/pubmed PY - 2016/11/1/medline KW - Chronic inflammatory demyelinating polyradiculoneuropathy KW - Guillain-Barré syndrome KW - IgM anti-myelin-associated-glycoprotein neuropathy KW - Immune-mediated neuropathies KW - Immunomodulatory treatments KW - Multifocal motor neuropathy SP - 96 EP - 107 JF - Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics JO - Neurotherapeutics VL - 13 IS - 1 N2 - Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms. SN - 1878-7479 UR - https://www.unboundmedicine.com/medline/citation/26602549/Immunotherapy_in_Peripheral_Neuropathies_ L2 - https://dx.doi.org/10.1007/s13311-015-0401-7 DB - PRIME DP - Unbound Medicine ER -